(NASDAQ: LPCN) Lipocine's forecast annual revenue growth rate of 112.64% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 118.38%, and while it is forecast to beat the US market's average forecast revenue growth rate of 23.25%.
Lipocine's revenue in 2026 is $4,322,693.On average, 4 Wall Street analysts forecast LPCN's revenue for 2026 to be $3,539,356, with the lowest LPCN revenue forecast at $2,176,357, and the highest LPCN revenue forecast at $4,955,098. On average, 4 Wall Street analysts forecast LPCN's revenue for 2027 to be $6,173,747, with the lowest LPCN revenue forecast at $5,929,462, and the highest LPCN revenue forecast at $6,356,961.
In 2028, LPCN is forecast to generate $289,944,045 in revenue, with the lowest revenue forecast at $278,573,690 and the highest revenue forecast at $298,471,811.